Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
anzurstobart (BMS-986351)
i
Other names:
BMS-986351, CC 95251, CC-95251
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
BMS
Drug class:
SIRPA antagonist
Related drugs:
‹
RRx-001 (2)
ADU-1805 (0)
ALTA-002 (0)
BI 765063 (0)
BI 770371 (0)
DS-1103 (0)
IBC0966 (0)
LM-101 (0)
RRx-001 (2)
ADU-1805 (0)
ALTA-002 (0)
BI 765063 (0)
BI 770371 (0)
DS-1103 (0)
IBC0966 (0)
LM-101 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab + BMS-986351
Sensitive: C3 – Early Trials
rituximab + BMS-986351
Sensitive
:
C3
rituximab + BMS-986351
Sensitive: C3 – Early Trials
rituximab + BMS-986351
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login